This assay included profiling of antigens (CD123, TIM-3, CD33, CD47, CD90, CD38, CD25, CD70 and U5 snRNP200) being actively assessed in clinical trials10–12 or previously described as putative AML-associated antigens13–15. This evidence concerns the gene THY1 and acute myeloid leukemia.